Luspatercept

Hematology / Anemia

Also known as: Reblozyl, ACE-536, Luspatercept-aamt

Activin Receptor TrapsResearch phase: FDA-approvedRegulatory: FDA-approved for anemia in MDS with ring sideroblasts (2020) and transfusion-dependent beta-thalassemia (2019). Expanded to first-line lower-risk MDS anemia (2023) (Reblozyl).

Mechanism

Luspatercept is a red blood cell maturation agent that treats anemia by a novel mechanism. It traps activin and GDF-11 — signals that block the final stages of red blood cell development in the bone marrow. By removing this brake, it allows more red blood cells to mature and enter the bloodstream. It is FDA-approved for anemia in myelodysplastic syndromes (MDS) and beta-thalassemia, reducing transfusion needs.

Technical detail

Luspatercept is a fusion protein of a modified extracellular domain of activin receptor type IIB (ActRIIB) linked to human IgG1 Fc. It traps TGF-beta superfamily ligands including GDF-11, activin A, and activin B that negatively regulate late-stage erythropoiesis (Smad2/3-mediated inhibition of erythroid differentiation). By sequestering these ligands, luspatercept promotes erythroid precursor maturation from basophilic to orthochromatic erythroblasts and reticulocyte release, complementing the early-stage erythropoietic effects of EPO. Distinct from sotatercept by its modified ActRIIB domain conferring different ligand-binding specificity.

Evidence

  • A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

    Cappellini MD et al. (2020) — N Engl J Med — PMID: 32212518

    Among adults with transfusion-dependent beta-thalassemia, luspatercept significantly improved the primary endpoint of at least 33% transfusion-burden reduction during weeks 13-24 versus placebo (21.4% vs 4.5%; P<0.001), with broader reductions seen across other 12-week intervals.

    strong
Build a personalized protocol with Luspatercept →